A Phase 4 interventional study of Metaxalone Pill and tizanidine 8 mg in Healthy Participant, sponsored by Primus Pharmaceuticals. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Primus Pharmaceuticals · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Participant takes a single pill after eating, takes a driving test on a simulator, takes thought and concentration computerized tests
The study evaluates effects of a single-dose of M640 mg compared to a single dose of tizanidine 8 mg on driving, cognition, sleepiness, and brain activity in healthy adults
Primus Pharmaceuticals is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
metaxalone 640 mg tablets, one dose only
Drug: Metaxalone Pill
tizanidine 8 mg tablets, one dose only
Drug: tizanidine 8 mg
micronized metaxalone 640 mg pill
Also known as: m640, Skelaxin 640 mg
muscle relaxer for spasms
Also known as: Zanaflex
Change from Baseline to Tmax in Standard Deviation of Lateral Position as evaluated by Driving Simulation Software
A hardware and software setup that recreates the experience of driving a real vehicle and measures performance at the time of maximum concentration of the drug in the body (metaxalone 4 hours and tizanidine 1.5 hours post dose)
Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours post dose
Change from Baseline to Tmax in Cognition as assessed by Creyos Cognitive Testing (CCT).
Computerized thinking assessment to objectively measure brain function at the time of maximum concentration of the drug in the body (metaxalone 4 hours and tizanidine 1.5 hours post dose)
Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours post dose
Change from Baseline to Tmax in Degree of point-in-time drowsiness as measured by the Karolinska Sleepiness Scale (KSS).
Measure at Tmax (metaxalone 4 hours and tizanidine 1.5 hours post dose) Scale: 1 = Extremely alert, 2 = Very alert, 3 = Alert, 4 = Rather alert, 5 = Neither alert nor sleepy, 6 = Some signs of sleepiness, 7 = Sleepy, but no effort to keep awake, 8 = Sleepy, some effort to keep awake, 9 = Very sleepy, great effort to keep awake, fighting sleep
Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours
Change from Baseline to Tmax in electroencephalograph measures
Placement of a non-invasive headset with saline filled, padded electrodes on the participant's scalp to measure brain activity with eyes open and closed at the time of maximum dose of the drug in the body (metaxalone 4 hours and tizanidine 1.5 hours post dose)
Time frame: Baseline dose to time of maximum concentration (Tmax), metaxalone 4 hours and tizanidine 1.5 hours post dose
Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metaxalone · Tizanidine
Primus Pharmaceuticals